Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major interstitial cystitis markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.07% during 2024-2034.
The interstitial cystitis market has been comprehensively analyzed in IMARC's new report titled "Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Interstitial cystitis, also referred to as painful bladder syndrome, is a chronic condition that causes pressure and pain in the pelvis or bladder. Women are more likely to develop the disease than men, and the condition can occur at any age. Interstitial cystitis is characterized by chronic pelvic pain, pain during intercourse, discomfort while the bladder fills, an urgent desire to urinate, and relief after urinating. The bladder or pelvic discomfort ranges from mild to severe among patients. Individuals suffering from interstitial cystitis may also experience interrupted sleep, resulting in depression and lower quality of life. The diagnosis of this condition is based on a combination of medical history, physical exam, and diagnostic tests. The doctor may perform a urine culture to rule out a urinary tract infection and conduct a cystoscopy to examine the bladder lining. In addition to this, the doctor may also recommend urodynamics testing to evaluate bladder function and capacity. IC is often a diagnosis of exclusion, meaning that other conditions with similar symptoms must be ruled out first.
The rising incidences of bladder damage or injury and chronic inflammation in the bladder lining are primarily driving the interstitial cystitis market. Moreover, the increasing prevalence of several associated risk factors, such as neurogenic inflammation, pelvic floor dysfunction, autoimmune disorders, etc., is positively influencing the market. In addition to this, the emerging popularity of microbiome-based therapies for alleviating indications, including pain, urinary frequency, urgency, etc., is also propelling the market growth. Furthermore, the escalating application of transcutaneous electrical nerve stimulation (TENS), since it aids in relieving symptoms by blocking the transmission of pain signals from the bladder to the brain and modulating nerve activity, is creating a positive outlook for the market. Apart from this, numerous key players are extensively focusing on the advancements of innovative treatments, such as gene and regenerative therapies, that have lesser side effects than conventional drugs. This, in turn, is also bolstering the market growth. Furthermore, the increasing utilization of sacral nerve stimulation implants for regulating bladder function and reducing the symptoms of the disease, including urinary urgency and frequency, in patients who have not responded to other treatments is expected to drive the interstitial cystitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the interstitial cystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for interstitial cystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the interstitial cystitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the interstitial cystitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the interstitial cystitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current interstitial cystitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the interstitial cystitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the interstitial cystitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the interstitial cystitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of interstitial cystitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with interstitial cystitis across the seven major markets?
What is the size of the interstitial cystitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of interstitial cystitis?
What will be the growth rate of patients across the seven major markets?
Interstitial Cystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for interstitial cystitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the interstitial cystitis market?
What are the key regulatory events related to the interstitial cystitis market?
What is the structure of clinical trial landscape by status related to the interstitial cystitis market?
What is the structure of clinical trial landscape by phase related to the interstitial cystitis market?
What is the structure of clinical trial landscape by route of administration related to the interstitial cystitis market?
The interstitial cystitis market has been comprehensively analyzed in IMARC's new report titled "Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Interstitial cystitis, also referred to as painful bladder syndrome, is a chronic condition that causes pressure and pain in the pelvis or bladder. Women are more likely to develop the disease than men, and the condition can occur at any age. Interstitial cystitis is characterized by chronic pelvic pain, pain during intercourse, discomfort while the bladder fills, an urgent desire to urinate, and relief after urinating. The bladder or pelvic discomfort ranges from mild to severe among patients. Individuals suffering from interstitial cystitis may also experience interrupted sleep, resulting in depression and lower quality of life. The diagnosis of this condition is based on a combination of medical history, physical exam, and diagnostic tests. The doctor may perform a urine culture to rule out a urinary tract infection and conduct a cystoscopy to examine the bladder lining. In addition to this, the doctor may also recommend urodynamics testing to evaluate bladder function and capacity. IC is often a diagnosis of exclusion, meaning that other conditions with similar symptoms must be ruled out first.
The rising incidences of bladder damage or injury and chronic inflammation in the bladder lining are primarily driving the interstitial cystitis market. Moreover, the increasing prevalence of several associated risk factors, such as neurogenic inflammation, pelvic floor dysfunction, autoimmune disorders, etc., is positively influencing the market. In addition to this, the emerging popularity of microbiome-based therapies for alleviating indications, including pain, urinary frequency, urgency, etc., is also propelling the market growth. Furthermore, the escalating application of transcutaneous electrical nerve stimulation (TENS), since it aids in relieving symptoms by blocking the transmission of pain signals from the bladder to the brain and modulating nerve activity, is creating a positive outlook for the market. Apart from this, numerous key players are extensively focusing on the advancements of innovative treatments, such as gene and regenerative therapies, that have lesser side effects than conventional drugs. This, in turn, is also bolstering the market growth. Furthermore, the increasing utilization of sacral nerve stimulation implants for regulating bladder function and reducing the symptoms of the disease, including urinary urgency and frequency, in patients who have not responded to other treatments is expected to drive the interstitial cystitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the interstitial cystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for interstitial cystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the interstitial cystitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the interstitial cystitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the interstitial cystitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current interstitial cystitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the interstitial cystitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the interstitial cystitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the interstitial cystitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of interstitial cystitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of interstitial cystitis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with interstitial cystitis across the seven major markets?
What is the size of the interstitial cystitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of interstitial cystitis?
What will be the growth rate of patients across the seven major markets?
Interstitial Cystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for interstitial cystitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the interstitial cystitis market?
What are the key regulatory events related to the interstitial cystitis market?
What is the structure of clinical trial landscape by status related to the interstitial cystitis market?
What is the structure of clinical trial landscape by phase related to the interstitial cystitis market?
What is the structure of clinical trial landscape by route of administration related to the interstitial cystitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTERSTITIAL CYSTITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTERSTITIAL CYSTITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTERSTITIAL CYSTITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INTERSTITIAL CYSTITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTERSTITIAL CYSTITIS - UNMET NEEDS
10 INTERSTITIAL CYSTITIS - KEY ENDPOINTS OF TREATMENT
11 INTERSTITIAL CYSTITIS - MARKETED PRODUCTS
11.1 List of Interstitial Cystitis Marketed Drugs Across the Top 7 Markets
11.1.1 Elmiron (Pentosan polysulfate sodium) - Bene-Arzneimittel/ReqMed
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTERSTITIAL CYSTITIS - PIPELINE DRUGS
12.1 List of Interstitial Cystitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Botox - AbbVie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SI722 - Seikagaku Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 URG101 - Urigen Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTERSTITIAL CYSTITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTERSTITIAL CYSTITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTERSTITIAL CYSTITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Interstitial Cystitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Interstitial Cystitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Interstitial Cystitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Interstitial Cystitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Interstitial Cystitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Interstitial Cystitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Interstitial Cystitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Interstitial Cystitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Interstitial Cystitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Interstitial Cystitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Interstitial Cystitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Interstitial Cystitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Interstitial Cystitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Interstitial Cystitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Interstitial Cystitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Interstitial Cystitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Interstitial Cystitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Interstitial Cystitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Interstitial Cystitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Interstitial Cystitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Interstitial Cystitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Interstitial Cystitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Interstitial Cystitis - Access and Reimbursement Overview
16 INTERSTITIAL CYSTITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTERSTITIAL CYSTITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTERSTITIAL CYSTITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTERSTITIAL CYSTITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTERSTITIAL CYSTITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTERSTITIAL CYSTITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INTERSTITIAL CYSTITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTERSTITIAL CYSTITIS - UNMET NEEDS
10 INTERSTITIAL CYSTITIS - KEY ENDPOINTS OF TREATMENT
11 INTERSTITIAL CYSTITIS - MARKETED PRODUCTS
11.1 List of Interstitial Cystitis Marketed Drugs Across the Top 7 Markets
11.1.1 Elmiron (Pentosan polysulfate sodium) - Bene-Arzneimittel/ReqMed
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTERSTITIAL CYSTITIS - PIPELINE DRUGS
12.1 List of Interstitial Cystitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Botox - AbbVie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SI722 - Seikagaku Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 URG101 - Urigen Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTERSTITIAL CYSTITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTERSTITIAL CYSTITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTERSTITIAL CYSTITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Interstitial Cystitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Interstitial Cystitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Interstitial Cystitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Interstitial Cystitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Interstitial Cystitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Interstitial Cystitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Interstitial Cystitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Interstitial Cystitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Interstitial Cystitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Interstitial Cystitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Interstitial Cystitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Interstitial Cystitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Interstitial Cystitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Interstitial Cystitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Interstitial Cystitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Interstitial Cystitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Interstitial Cystitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Interstitial Cystitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Interstitial Cystitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Interstitial Cystitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Interstitial Cystitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Interstitial Cystitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Interstitial Cystitis - Access and Reimbursement Overview
16 INTERSTITIAL CYSTITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTERSTITIAL CYSTITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTERSTITIAL CYSTITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
